![Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: A retrospective cohort study - The Lancet Regional Health – Americas Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: A retrospective cohort study - The Lancet Regional Health – Americas](https://www.thelancet.com/cms/asset/d17f8c7e-ef09-420d-8007-d11155f47788/gr1.jpg)
Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: A retrospective cohort study - The Lancet Regional Health – Americas
![Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil | Nature Communications Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-022-33169-0/MediaObjects/41467_2022_33169_Fig1_HTML.png)
Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil | Nature Communications
![Rollout Strategy for the Pfizer-BioNTech COVID-19 Vaccine in Ontario - Ontario COVID-19 Science Advisory Table Rollout Strategy for the Pfizer-BioNTech COVID-19 Vaccine in Ontario - Ontario COVID-19 Science Advisory Table](https://covid19-sciencetable.ca/wp-content/uploads/2020/12/Figure-1.jpg)
Rollout Strategy for the Pfizer-BioNTech COVID-19 Vaccine in Ontario - Ontario COVID-19 Science Advisory Table
![Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials - The Lancet Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials - The Lancet](https://www.thelancet.com/cms/attachment/db5c63dc-ee49-4b78-b05c-e93ffa8229af/gr1_lrg.jpg)
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials - The Lancet
![Cohort study of Covid-19 vaccine effectiveness among healthcare workers in Finland, December 2020 - October 2021 - ScienceDirect Cohort study of Covid-19 vaccine effectiveness among healthcare workers in Finland, December 2020 - October 2021 - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0264410X21016406-gr1.jpg)
Cohort study of Covid-19 vaccine effectiveness among healthcare workers in Finland, December 2020 - October 2021 - ScienceDirect
![Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study - The Lancet Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study - The Lancet](https://www.thelancet.com/cms/attachment/a3e48024-327b-4760-9da1-13676e339e37/gr1_lrg.jpg)
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study - The Lancet
![Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant — United States, February 14–March 27, 2022 | MMWR Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant — United States, February 14–March 27, 2022 | MMWR](https://www.cdc.gov/mmwr/volumes/71/wr/figures/mm7118a4-F-large.gif?_=74292)
Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant — United States, February 14–March 27, 2022 | MMWR
![Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK - The Lancet Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK - The Lancet](https://www.thelancet.com/cms/asset/f3be98d8-d68c-4273-a286-fc9e5079f0d6/gr1.jpg)
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK - The Lancet
![Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study - The Lancet Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study - The Lancet](https://www.thelancet.com/cms/attachment/97d1c5ff-af79-4d10-b5b8-3026a35a572d/gr1_lrg.jpg)
Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study - The Lancet
![Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing ... Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing ...](https://www.cdc.gov/mmwr/volumes/72/wr/social-media/mm7205e1_BivalentVECurrentSublineages_IMAGE_25Jan2023_1200x675-medium.jpg?_=95835)